What Matters for Health Centers
The 340B Drug Pricing Program is an essential source of support for Community Health Centers, allowing them to stretch increasingly scarce federal resources and reinvest in patient care. The program allows health centers to purchase outpatient drugs at significantly reduced costs. Health centers pass the savings on to their patients through reduced drug prices, and use any additional savings in support of their mission to expand access and improve health outcomes among medically underserved populations. This translates to better patient care in any variety of ways, including through improved pharmacy access, extended health center hours, or the ability to provide additional providers or services.
Quick References
2018 NACHC Policy Paper: 340B
NACHC Infographic: The Nuts and Bolts of 340B
Important Links
Suggested Template for One-Pager Describing Impact of Contract Pharmacy
Operational Support for Health Centers with 340B Programs
NACHC 340B Manual Second edition (available for free to organizations that purchased the first edition).
NACHC’s Monthly 340B/Pharmacy Office Hours are held the third Thursday of each month except in March and August at 2:00pm eastern time. Learn more.
Apexus Advanced 340B Operations Certificate Program
Health centers that participate in the Apexus certificate program can receive a $100 discount by using the code NACHC2018.
Capitol Hill Activity on 340B
-
- House Energy and Commerce Committee Report: “Review of the 340B Drug Pricing Program” (January 2018)
- Congressional hearings on the 340B program:
July 2018 – House Energy and Commerce Committee hearing, “Opportunities to Improve the 340B Drug Pricing Program”
June 2018 – Senate Health, Education, Labor and Pensions Committee Hearing, “Effective Administration of the 340B Drug Pricing Program”
May 2018 – Senate Health, Education, Labor and Pensions Committee Hearing, Examining Oversight Reports on the 340B Drug Pricing Program”
March 2018 – Senate Health, Education, Labor and Pensions Committee Hearing, “Perspectives on the 340B Drug Pricing Program”
October 2017 – House Energy and Commerce Subcommittee on Oversight and Investigations Hearing, “Examining How Covered Entities Utilize the 340B Drug Pricing Program”
July 2017 – House Energy and Commerce Subcommittee on Oversight and Investigations Hearing, “Examining HRSA’s Oversight of the 340B Drug Pricing Program”
GAO Report: “Drug Discount Program: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement”(July 2018)
E&C Chairmen
Letters to Select Contract Pharmacies (August 2018)
Chairmen Hatch and Walden Letter to OMB regarding PBM Rebates (August 2018)
Bipartisan HELP/ E&C Letter Urging HRSA to Use Existing Authorities (August 2018)